News

Nasoni Takes the Lead in Transforming Care for Alzheimer’s and Dementia Patients with $2.4M Federal Grant

Hampton Roads stands at the forefront of innovation by announcing a $2.4 million federal grant to enhance care for Alzheimer’s and dementia patients. This funding, spearheaded by Congresswoman Jen Kiggans, not only highlights the region’s commitment to healthcare but also emphasizes the role of local startups like Nasoni, which are driving the future of patient care.

Nasoni, a forward-thinking Hampton Roads startup known for its innovative faucet designs, is expanding its reach into healthcare with solutions that improve the quality of life for patients facing cognitive challenges. As part of the broader effort supported by the federal grant, Nasoni will play a crucial role in developing practical, user-friendly technologies to assist patients and caregivers alike.

Their patented faucets, designed with ease of use in mind, are particularly valuable for individuals with Alzheimer’s and dementia. With simple features that allow for better access to clean water, Nasoni’s faucets reduce daily stress and improve hydration—an often overlooked but critical aspect of care for aging populations.

Founder Steve Waddell is optimistic about Nasoni’s impact. “Our goal has always been to make life easier through innovative design,” Waddell says. With this grant, we can extend that mission to vulnerable populations in Hampton Roads, providing practical solutions that ease the burdens of care.”

Kiggans, a former geriatric nurse practitioner, recognizes the importance of such local innovations. “Companies like Nasoni are key to revolutionizing the way we support Alzheimer’s and dementia patients. Their commitment to improving everyday tasks like access to clean water aligns with our goal of enhancing patient care in meaningful ways,” she shared during the announcement.

In addition to Nasoni’s contributions, the grant will fund various community-based programs, caregiver training, and healthcare initiatives designed to enhance early detection and personalized care strategies. By combining Nasoni’s innovative products with these expanded services, Hampton Roads is set to become a model for Alzheimer’s and dementia care.

The collaboration between local businesses and healthcare providers underscores the region’s thriving ecosystem of startups and technology. As Nasoni continues to expand its influence, its work will serve as a shining example of how ingenuity can positively impact patient care on a large scale.

This grant not only advances the fight against Alzheimer’s and dementia but also highlights the role of Hampton Roads startups in solving critical healthcare challenges. With Nasoni’s help, the future of care in the region looks brighter than ever.

 

Read more here.

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients